Why does the V1613M variant reduce amyloid pathology when ABCA7 loss-of-function increases AD risk?

PARTIALLY ADDRESSED

The abstract shows V1613M variant reduces amyloid plaques and damage in 5xFAD mice, yet ABCA7 loss-of-function mutations increase LOAD risk. This apparent contradiction suggests complex genotype-phenotype relationships that could inform therapeutic targeting. Gap type: contradiction Source paper: The Abca7 (None, None, PMID:38506634)

Priority: 0.89 Domain: neurodegeneration Hypotheses: 0

📊 Landscape Analysis

Landscape Summary: Why does the V1613M variant reduce amyloid pathology when ABCA7 loss-of-function increases AD risk? is a 0.89 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: partially_addressed.

Key Unanswered Questions

What is the optimal TREM2 modulation strategy across disease stages?
How does DAM activation state affect therapeutic outcomes?
What biomarkers predict response to TREM2-targeted interventions?

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

Why does the V1613M variant reduce amyloid pathology when ABCA7 loss-of-function increases AD risk? — INVOKE-2 (completed)

📈 Living Dashboards

0

Hypotheses

0.000

Top Score

0.000

Avg Score

0

Debates

0.00

Avg Quality

60%

Resolution

0

Mechanistic Families

Gap Resolution Progress60%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

associated with (10)

entities-histone-methylation→ADentities-ros→ADentities-atp7b-gene→ADALZHEIMER'S DISEASE→ABCA7TDP-43→AD

▸ Show 5 more

TAU→ADAPOE→ADAMYLOID→ABCA7MIR-146A→ADABCA7→BDNF

causes (1)

AD→neurodegeneration

contributes to (1)

ABCA7→mitochondrial_dysfunction

cross disease mechanism in (3)

MAPT→ADTREM2→ADNLRP3→AD

data in (7)

ad_genetic_risk_loci:ABCA7→ABCA7ABCA7→benchmark_ot_ad_answer_key:ABCA7benchmark_ot_ad_answer_key:ABCA7→ABCA7ABCA7→ad_genetic_risk_loci:ABCA7ds-83b31ef18d49→ABCA7

▸ Show 2 more

ds-db4a006ea647→ABCA7ds-f50762b67605→ABCA7

describes (1)

genes-abca7→ABCA7

expressed in (3)

ABCA7→MacrophagesABCA7→neuronsABCA7→stem cells

increases risk (1)

ABCA7→alzheimer_disease

induces (1)

ABCA7→Neuropeptide Y

interacts with (3)

ABCA7→ATPAPOE2→ABCA7ABCA7→ApoE particles

involved in (1)

ABCA7→Microglial Aβ Clearance

mediates (1)

ABCA7→Phagocytosis

member of (1)

ABCA7→R-HSA-1369062

modulates (3)

ABCA7→APP ProcessingABCA7→Lipid ProcessingABCA7→Cholesterol Transport

provides data for (3)

ABCA7→ds-db4a006ea647ABCA7→ds-f50762b67605ABCA7→ds-83b31ef18d49

regulates (3)

ABCA7→PhagocytosisABCA7→Phospholipid HomeostasisABCA7→cholesterol transport

risk factor for (3)

ABCA7→Alzheimer's DiseaseAPOE ε4→ADgenetically at-risk individuals→AD

therapeutic target for (2)

TREM2→ADCCR2→AD

transports (2)

ABCA7→Amyloid-βABCA7→Oxidized Unsaturated Lipids

🕑 Activity Feed

✏ update on knowledge_gap by max_gmail 2026-04-28T00:44

✏ update on knowledge_gap by None 2026-04-25T22:15

✏ update on knowledge_gap by None 2026-04-14T11:26

✏ update on knowledge_gap by None 2026-04-14T11:26

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

Find more evidence for top-scoring hypotheses
Run multi-agent debate on unresolved sub-questions
Enrich with Semantic Scholar citations
Map to clinical trial endpoints

← Back to All Gaps